Relevance of treatment‐free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors

BACKGROUND: Tyrosine kinase inhibitors (TKI) can be safely discontinued in chronic phase chronic myeloid leukemia (CP‐CML) patients who had achieved a sustained deep molecular response. Based on the results of discontinuation trials, recommendations regarding patient selection for a treatment‐free r...

Descripción completa

Detalles Bibliográficos
Autores principales: Etienne, Gabriel, Faberes, Carole, Bauduer, Fréderic, Adiko, Didier, Lifermann, François, Dagada, Corinne, Lenoir, Caroline, Schmitt, Anna, Klein, Emilie, Fort, Marie‐Pierre, Bijou, Fontanet, Turcq, Beatrice, Robbesyn, Fanny, Durrieu, Françoise, Versmée, Laura, Madene, Samia, Moldovan, Marius, Katsahian, Sandrine, Charles‐Nelson, Anais, Lascaux, Axelle, Mahon, François‐Xavier, Dulucq, Stéphanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178499/
https://www.ncbi.nlm.nih.gov/pubmed/33988316
http://dx.doi.org/10.1002/cam4.3921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178499/
https://www.ncbi.nlm.nih.gov/pubmed/33988316
http://dx.doi.org/10.1002/cam4.3921

Ejemplares similares